Loading…
Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.
Italian in-vitro diagnostics maker of immunodiagnostic and molecular test kits and analyzers for infectious disease and other conditions.
Places analyzers in laboratories, often on loan or lease, and earns from the test kits the analyzers consume, so each installed machine produces repeat revenue; the more tests offered on one analyzer, the more reason a lab has to stay. The 2021 purchase of Luminex added a molecular-testing platform.
In one line: A mid-cap diagnostics maker like Quidel Ortho.
Moat: narrow (installed base, switching costs, IP / patents). Closed-system analyzers lock customers into DiaSorin's proprietary reagents once installed.
Headquarters: Saluggia, Italy · Founded: 1968 · Employees: 3,272
Size DiaSorin (DIA.MI) is an Italy Health Care company (Medical Specialties) with a market value of $5.00B, the 45th largest of 123 Italy companies the cockpit tracks. Shares closed at €82.64 on 6 Nov 2026.
Performance Over six months the shares gained 19.0%, against +27.7% for the median peer and +3.1% for the Italy market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 3.1% over the last twelve months (peer median +6.9%); the operating margin is 23.6% (peer median 13.3%).
Valuation It trades at 20.6× forward earnings against a peer median of 19.7× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.7 points above its cost of capital (6.2% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.18B | €1.20B | €1.19B | €1.15B | €1.36B |
| Revenue growth | — | +1% | +3% | -16% | — |
| Gross profit | €683M | €700M | €708M | €669M | €827M |
| EBITDA | €405M | €433M | €407M | €351M | €502M |
| Net income | €141M | €156M | €188M | €160M | €241M |
| Free cash flow | €238M | €281M | €307M | €266M | €336M |
| Capital expenditure | €130M | €138M | €120M | €113M | €114M |
| Total debt | n/a | €791M | €1.01B | €1.19B | €1.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| DiaSorin DIA.MI | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% |
| bioMerieux BIM.PA | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DIA.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.6% | +10.1% | 11th highest of 21 |
| 6-month return | +19.0% | +27.7% | 8th lowest of 21 |
| Distance from 52-week high | -0.1% | -10.1% | highest of 21 |
| Revenue growth (TTM) | -3.1% | +6.9% | 4th lowest of 20 |
| Operating margin | 23.6% | 13.3% | 5th highest of 21 |
| Forward P/E | 20.6× | 19.7× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 4.1% | 11.9% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +6.3% | +8.6% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | -2.2 pp | +2.4 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +2.7 pp | +2.2 pp | 9th highest of 20 |
| EV / EBITDA | 13.1× | 15.4× | 6th cheapest of 15 |
| Net debt / EBITDA | 2.1× | 1.1× | 7th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% | +11.9% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |